Ninety percent of clinical drug development fails despite implementation of many successful
strategies, which raised the question whether certain aspects in target validation and drug …

Lung cancer has traditionally been classified by histology. However, a greater
understanding of disease biology and the identification of oncogenic driver alterations has …

PURPOSE Standard first-line therapy for EGFR-mutant advanced non–small-cell lung
cancer (NSCLC) is an epidermal growth factor receptor (EGFR)–directed oral tyrosine …

Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …

ABSTRACT Background In LUX-Lung 7, the irreversible ErbB family blocker, afatinib,
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …

The traditional approach to the treatment of patients with advanced-stage non-small-cell
lung carcinoma (NSCLC) harbouring ALK rearrangements or EGFR mutations has been the …

Background We aimed to assess the effect of afatinib on overall survival of patients with
EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open …

Background Most patients with non-small-cell lung cancer tumours that have EGFR
mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21 …

Background In AURA3 (NCT02151981), osimertinib, a third-generation epidermal growth
factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), significantly prolonged progression …

Front-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) therapy is
the standard of care for lung cancer patients with sensitising EGFR mutations (exon 19 …